- Home
- SITC vs DCTH Comparison
SITC vs DCTH Comparison
Compare SITC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- DCTH
- Stock Information
- Founded
- SITC 1965
- DCTH 1988
- Country
- SITC United States
- DCTH United States
- Employees
- SITC N/A
- DCTH N/A
- Industry
- SITC Real Estate Investment Trusts
- DCTH Medical/Dental Instruments
- Sector
- SITC Real Estate
- DCTH Health Care
- Exchange
- SITC Nasdaq
- DCTH Nasdaq
- Market Cap
- SITC 603.6M
- DCTH 630.4M
- IPO Year
- SITC 1993
- DCTH N/A
- Fundamental
- Price
- SITC $11.92
- DCTH $16.30
- Analyst Decision
- SITC Hold
- DCTH Strong Buy
- Analyst Count
- SITC 8
- DCTH 4
- Target Price
- SITC $35.25
- DCTH $24.00
- AVG Volume (30 Days)
- SITC 558.3K
- DCTH 610.5K
- Earning Date
- SITC 05-07-2025
- DCTH 05-08-2025
- Dividend Yield
- SITC 4.40%
- DCTH N/A
- EPS Growth
- SITC 151.17
- DCTH N/A
- EPS
- SITC 10.32
- DCTH N/A
- Revenue
- SITC $227,525,000.00
- DCTH $53,850,000.00
- Revenue This Year
- SITC N/A
- DCTH $141.47
- Revenue Next Year
- SITC $17.57
- DCTH $49.31
- P/E Ratio
- SITC $1.15
- DCTH N/A
- Revenue Growth
- SITC N/A
- DCTH 1068.87
- 52 Week Low
- SITC $10.46
- DCTH $6.33
- 52 Week High
- SITC $18.15
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- SITC 46.67
- DCTH 58.68
- Support Level
- SITC $11.55
- DCTH $15.73
- Resistance Level
- SITC $12.05
- DCTH $17.29
- Average True Range (ATR)
- SITC 0.25
- DCTH 0.96
- MACD
- SITC -0.02
- DCTH -0.08
- Stochastic Oscillator
- SITC 31.62
- DCTH 50.58
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.